Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $10.07M by Medicaid between Jan 2018 and Dec 2024, across 151 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
VACAVILLE, CA 95688
VACAVILLE, CA 95688
33aNPI1710116116assigned 07/07/2009
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.07M
24GClaims133,914
24DCodes billed151
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#179 of 410
Median peer was paid$6.90M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 247 | $12K | |
| 2019 | 978 | $11K | |
| 2020 | 1,477 | $44K | |
| 2021 | 3,108 | $69K | |
| 2022 | 4,919 | $173K | |
| 2023 | 7,802 | $193K | |
| 2024incomplete | 115,383 | $9.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 2,711 | 2,550 | $3.05M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 2,782 | 2,632 | $1.35M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 2,620 | 2,549 | $1.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 650 | 619 | $1.07M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.7% | 3,205 | 3,075 | $477K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 749 | 731 | $440K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 1,241 | 1,214 | $171K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.6% | 1,911 | 1,871 | $158K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 1,322 | 1,250 | $144K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 752 | 738 | $130K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 253 | 251 | $95K |
| 76830 | Ultrasound, transvaginal | <1% | 533 | 531 | $94K |
139 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 251 | $93K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 550 | $90K |
| 73630 | <1% | 647 | $87K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 427 | $75K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 448 | $73K |
| G0378 | Hospital observation service, per hour | <1% | 767 | $69K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 196 | $68K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 236 | $66K |
| 73610 | <1% | 450 | $65K | |
| 73130 | <1% | 367 | $52K | |
| 73110 | <1% | 335 | $50K | |
| 73030 | <1% | 383 | $48K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 113 | $48K |
| 73564 | <1% | 286 | $48K | |
| 73560 | <1% | 315 | $46K | |
| 74018 | <1% | 281 | $41K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,448 | $39K |
| 72100 | <1% | 225 | $37K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 182 | $35K |
| 76770 | <1% | 200 | $34K | |
| 0450 | Emergency room services | <1% | 763 | $34K |
| 73140 | <1% | 221 | $31K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,596 | $27K |
| 73502 | <1% | 208 | $27K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 134 | $25K |
| 73080 | <1% | 164 | $23K | |
| 72040 | <1% | 161 | $22K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,698 | $22K |
| 77080 | <1% | 143 | $20K | |
| 72141 | <1% | 45 | $19K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 28 | $18K |
| 86900 | <1% | 295 | $17K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,384 | $15K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 75 | $13K |
| 71250 | <1% | 62 | $13K | |
| 73590 | <1% | 89 | $13K | |
| 81001 | <1% | 4,378 | $11K | |
| 83880 | <1% | 483 | $11K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 40 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,932 | $10K |
| 82565 | <1% | 6,392 | $10K | |
| 76857 | <1% | 53 | $9K | |
| 80051 | <1% | 5,485 | $9K | |
| 93971 | <1% | 58 | $8K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 37 | $7K |
| 84702 | <1% | 710 | $7K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 658 | $7K |
| 86850 | <1% | 233 | $7K | |
| 76536 | <1% | 30 | $6K | |
| 82247 | <1% | 2,964 | $6K | |
| 84460 | <1% | 3,025 | $6K | |
| 73221 | <1% | 13 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 972 | $5K |
| 86901 | <1% | 295 | $5K | |
| 0270 | <1% | 734 | $5K | |
| 82947 | <1% | 5,613 | $4K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 233 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,189 | $4K |
| 84450 | <1% | 2,597 | $4K | |
| 84520 | <1% | 5,512 | $4K | |
| 85652 | <1% | 936 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 603 | $3K |
| 96376 | <1% | 344 | $3K | |
| 0637 | <1% | 13,097 | $3K | |
| 70486 | <1% | 13 | $3K | |
| 81003 | <1% | 1,993 | $3K | |
| 73090 | <1% | 15 | $3K | |
| 74022 | <1% | 12 | $2K | |
| J3490 | Unclassified drugs | <1% | 847 | $2K |
| 83735 | <1% | 1,234 | $2K | |
| 84484 | <1% | 1,091 | $2K | |
| 76870 | <1% | 13 | $2K | |
| 84075 | <1% | 2,127 | $2K | |
| 84132 | <1% | 367 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 114 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,128 | $2K |
| 97162 | <1% | 119 | $2K | |
| 83690 | <1% | 1,944 | $2K | |
| 82248 | <1% | 456 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 913 | $1K |
| 82570 | <1% | 253 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 756 | $1K |
| 82310 | <1% | 265 | $1K | |
| 84100 | <1% | 653 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 131 | $1K |
| 85610 | <1% | 545 | $914.41 | |
| 84156 | <1% | 237 | $835.64 | |
| 85027 | <1% | 184 | $730.85 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 367 | $705.99 |
| 85379 | <1% | 167 | $674.63 | |
| 86140 | <1% | 211 | $659.68 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 550 | $653.35 |
| 87324 | <1% | 53 | $601.00 | |
| 87449 | <1% | 55 | $559.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 354 | $529.05 |
| 84703 | <1% | 692 | $505.12 | |
| 82962 | <1% | 853 | $495.42 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,054 | $469.09 |
| 87088 | <1% | 662 | $418.72 | |
| 85730 | <1% | 78 | $378.70 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 963 | $348.59 |
| 0250 | <1% | 1,716 | $321.05 | |
| 82040 | <1% | 89 | $298.72 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 98 | $291.37 |
| 82077 | <1% | 368 | $280.69 | |
| 82803 | <1% | 61 | $206.70 | |
| 99070 | <1% | 51 | $206.20 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 592 | $192.76 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 603 | $188.74 |
| 84295 | <1% | 36 | $185.00 | |
| 87040 | <1% | 445 | $170.58 | |
| 83605 | <1% | 474 | $165.17 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 140 | $134.17 |
| Z7502 | <1% | 13 | $133.30 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 550 | $108.56 |
| 87081 | <1% | 72 | $93.76 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 329 | $80.80 |
| J1815 | Injection, insulin, per 5 units | <1% | 445 | $66.29 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 24 | $62.34 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 24 | $62.14 |
| 80179 | <1% | 176 | $59.64 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 193 | $46.65 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 63 | $41.15 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 54 | $38.75 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 272 | $38.25 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 195 | $29.45 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 326 | $14.91 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 27 | $13.38 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 123 | $5.64 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 49 | $5.58 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 20 | $0.00 |
| 76376 | 0% | 116 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 31 | $0.00 |
| 80306 | 0% | 58 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 13 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 26 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 29 | $0.00 |
| 80349 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJEMJEMIAN, NORAIR (SENIOR VICE PRESIDENT/ AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Vallejo, CA | $19.06M |
| Kaiser Foundation Hospitals | Vallejo, CA | $817K |
| Kaiser Foundation Hospitals | Vallejo, CA | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.